MiR-148b inhibits glycolysis in gastric cancer through targeting SLC2A1.
Ontology highlight
ABSTRACT: Although the molecular biology of GC has been well characterized, early diagnostic biomarkers and effective therapeutic options in gastric cancer are still under investigation. Here, we found that miR-148b expression decreased in human gastric cancer tissues compared with matched adjacent nontumor tissues by q-PCR analysis and in situ hybridization. Further investigation revealed that overexpression of miR-148b limited glycolysis including glucose consumption, lactate production in gastric cancer cell lines BGC-823 and MKN45. Bioinformatics prediction uncovered that a dedicated transporters solute carrier family 2 member 1 (SLC2A1), also called GLUT1, was the direct target of miR-148b. The target effects were further confirmed by luciferase assay and western blot analysis. Besides, a rever
SUBMITTER: Ding X
PROVIDER: S-EPMC5463086 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA